Lipase mutant and application thereof in synthesis of functional lipid OPL

By performing specific site mutations and host cell expression on lipase, the specific vitality of lipase is improved, and the problems of low OPL synthesis efficiency and insufficient product diversity in the prior art are solved, and efficient and economical OPL synthesis is achieved to meet the needs of the following problems. The demand for similar structures of breast milk fat.

CN118910004AActive Publication Date: 2024-11-08QINGDAO VLAND BIOTECH GRP CO LTD

Patent Information

Application Number
CN202411108696.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-08
Estimated Expiration
2044-08-13

AI Technical Summary

Technical Problem

The prior art lipase synthesis method of the highest content of triglyceride OPL in synthetic breast milk has problems of low efficiency and insufficient product diversity, and it is difficult to fully simulate the triglyceride composition of breast milk fat.

Method used

By mutation of lipase, especially the introduction of mutations at amino acid sites such as E287S, V306T, E335A, and D359L, the specific vitality of lipase is significantly improved, and combined with specific host cell expression vectors and enzyme activity detection methods, efficient OPL synthesis.

Benefits of technology

It significantly improves the specific vitality of lipase, reduces production costs, and achieves high product purity and yield in OPL synthesis, meeting the demand for similar structures of breast milk fat.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to the technical field of gene engineering and protein modification, in particular to a lipase mutant and application thereof in synthesis of functional lipid OPL. On the basis of wild type lipase RCL, mutants respectively containing single point mutations of E287S, V306T, E335A and D359L and combinations thereof are provided, and the specific activity of the lipase can be remarkably improved. The lipase mutant can be widely applied to synthesis of functional lipid OPL and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering and protein modification, and specifically relates to a lipase mutant and application thereof in synthesizing functional lipid OPL. Background Art

[0002] Lipase is a type of hydrolase that can hydrolyze triglycerides to generate free fatty acids and glycerol of different chain lengths. From the perspective of catalytic properties, lipase has mild reaction conditions, few by-products, and does not require coenzymes. It also has high chemical selectivity and stereoisomerism. At the same time, lipase also has the functions of catalyzing ester hydrolysis, ester synthesis, transesterification, aminolysis, alcoholysis, and drug synthesis.

[0003] The main sources of lipase are plants, animals and microorganisms. Microorganisms are characterized by a wide variety of species, rapid reproduction and easy mutation. They secrete a wide variety of lipases, have a wide spectrum of substrates, and can adapt to different pH values ​​and temperature ranges. Some microbial strains obtained from extreme environments have more prominent enzymatic properties. At present, it has been found that lipase-producing microorganisms are widely distributed, and more than 60 genera have been isolated and identified, including 10 genera of yeast, 23 genera of other fungi, 4 genera of actinomycetes, and 28 genera of bacteria. Fungal strains with high lipase production are mostly derived from Rhizopus, Aspergillus, Penicillium, Mucor, Geotrichum, etc.

[0004] Breast milk is the best food source for infants. It can meet the needs of infants for various nutrients, greatly reduce their chances of suffering from diarrhea, infectious diseases, allergic diseases and malnutrition, reduce infant mortality, and reduce the risk of chronic diseases in adulthood. Breast milk contains 3%-5% fat, including 98% triglycerides, 1% phospholipids, 0.5% cholesterol and cholesterol esters, and other fat accompaniments. As scientists progress in the study of breast milk lipids, the industry has proposed more and more human milk substitute fat structures similar to breast milk fat, such as OPO, OPL, UPU, etc., which are more familiar to everyone.

[0005] OPO is a well-known nutrient in infant formula. The full name of OPO is 1,3-dioleoyl-2-palmitoylglycerol, which is one of the triglycerides with the highest content in human milk. As a human milk substitute, OPO simulates a triglyceride in breast milk fat, but there are many types of triglycerides with similar structures in breast milk fat. It is difficult to make the overall fatty acid composition and its position distribution similar to breast milk fat by adding only one OPO, so it is not a full-price human milk substitute. In addition, research results on the composition of breast milk in various countries show that there are great differences between the components of breast milk in various countries. For example, the content of OPO is the highest in European and American breast milk, while the highest content in Chinese breast milk is not OPO, but OPL, that is, 1-oleic acid-2-palmitic acid-3-linoleoylglycerol.

[0006] At present, the enzymatic method is mainly used to synthesize OPO and OPL. Its advantages are mild reaction conditions, environmental friendliness, product safety, and lipase can be easily separated from the product. The acid hydrolysis method used in the enzymatic synthesis of OPO mainly uses palmitic acid-rich oils and oleic acid at the sn-2 position as substrates, and reacts under the action of sn-1,3-specific lipases. This method can prepare products with high purity and few by-products. The enzymatic synthesis of OPL requires the use of palmitic acid-rich oils and linoleic acid at the sn-2 position as substrates for enzymatic synthesis. At present, the development of lipases suitable for OPL synthesis is a research hotspot in this field. Summary of the invention

[0007] In order to solve the problems in the prior art, the present invention provides a lipase mutant with improved specific activity and application of the lipase mutant in synthesizing functional lipid OPL.

[0008] The present invention provides a lipase mutant, which comprises an amino acid sequence having at least 90% identity with SEQ ID NO:2, and comprises an amino acid substitution at at least one position selected from the following group: 287, 306, 335, 359 compared with SEQ ID NO:2.

[0009] In some embodiments of the invention, the amino acid sequence of the mutant is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to SEQ ID NO:2.

[0010] In some more specific embodiments, the amino acid sequence of the mutant is at least 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or at least 99.9% identical to SEQ ID NO:2.

[0011] In some embodiments of the present invention, the mutant comprises substitution of at least one amino acid in the following group: E287S, V306T, E335A, D359L.

[0012] In some embodiments of the present invention, the mutant comprises a substitution or a combination of substitutions of at least one amino acid in the following group:

[0013] E287S;

[0014] V306T;

[0015] E335A;

[0016] D359L;

[0017] E287S / V306T;

[0018] E287S / E335A;

[0019] E287S / D359L;

[0020] V306T / E335A;

[0021] V306T / D359L;

[0022] E335A / D359L;

[0023] E287S / V306T / E335A;

[0024] E287S / V306T / D359L;

[0025] E287S / E335A / D359L;

[0026] V306T / E335A / D359L;

[0027] E287S / V306T / E335A / D359L.

[0028] In some embodiments of the present invention, the amino acid sequence of the mutant is SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 9.

[0029] The present invention also relates to a DNA molecule encoding the above lipase mutant.

[0030] The present invention also relates to a recombinant expression vector comprising the above DNA molecule.

[0031] The present invention also relates to a host cell, comprising the above recombinant expression vector.

[0032] When the above plasmid is transferred into host cells, the specific activity of the recombinantly expressed lipase mutant is significantly improved.

[0033] The host cell is Pichia pastoris.

[0034] The host cell is Aspergillus niger.

[0035] The host cell is Trichoderma reesei.

[0036] The present invention also relates to the application of the lipase mutant in the synthesis of functional lipid OPL.

[0037] The present invention provides a mutant comprising single point mutations E287S, V306T, E335A, D359L and their combination based on wild-type lipase RCL, which can significantly improve the specific activity of lipase. The lipase mutant can be widely used in the synthesis of functional lipid OPL, and has broad application prospects. DETAILED DESCRIPTION

[0038] The method of the present invention is further described below with reference to examples. The experimental methods in the following examples that do not specify specific conditions can usually be operated under conventional conditions, such as the conditions described in the "Molecular Cloning Experiment Guide" compiled by J. Sambrook et al., or under the conditions recommended by the manufacturer. Those skilled in the art can better understand and grasp the present invention with the help of the examples. However, the protection and claims of the present invention are not limited to the specific cases provided, but should include the scope of protection that can be expanded by those skilled in the art on the basis of this specification without creative work.

[0039] Experimental materials and reagents:

[0040] Strains and vectors: Escherichia coli DH5α, Pichia pastoris GS115, and vector pPIC9k were purchased from Invitrogen.

[0041] Enzymes and kits: PCR enzyme and ligase were purchased from Takara, restriction endonucleases were purchased from Fermentas, and plasmid extraction kit and gel purification recovery kit were purchased from Omega.

[0042] Culture medium formula:

[0043] Escherichia coli culture medium (LB medium): 0.5% yeast extract, 1% peptone, 1% NaCl, pH 7.0;

[0044] LB+Amp medium: LB medium plus 100 μg / mL ampicillin;

[0045] LB+Kana medium: LB medium plus 50 μg / mL kanamycin;

[0046] Yeast medium (YPD medium): 1% yeast extract, 2% peptone, 2% glucose;

[0047] Yeast screening medium (MD medium): 2% glucose, 1.34% YNB, 4×10 -5 % biotin, 2% agar powder;

[0048] BMGY medium: 2% peptone, 1% yeast extract, 100 mM potassium phosphate buffer (pH 6.0), 1.34% YNB, 4×10 -5 % biotin, 1% glycerol;

[0049] BMMY medium: 2% peptone, 1% yeast extract, 100 mM potassium phosphate buffer (pH 6.0), 1.34% YNB, 4×10 -5 % biotin, 0.5% methanol.

[0050] The present invention is described in detail below with reference to the embodiments.

[0051] Example 1 Obtaining a single-point mutant of lipase with high specific activity

[0052] 1.1 Amplification of lipase gene

[0053] The wild-type lipase gene from Rhizopus oryzae was named RCL, the nucleotide sequence of which is SEQ ID NO: 1, and the encoded amino acid sequence of which is SEQ ID NO: 2. The gene was synthesized by Shanghai Jierui Biotechnology Co., Ltd.

[0054] The PCR primers designed at the 5' end of the gene contain an EcoRI endonuclease site, and the PCR primers designed at the 3' end contain a NotI endonuclease site. The primer sequences are as follows:

[0055] 5' primer RCL-F: GGC GAATTC GTCCCTGTCTCCGGTAAATCC (the underline indicates the restriction endonuclease EcoRI recognition site);

[0056] 3' primer RCL-R:ATA GCGGCCGC TTACAGGCAGGAGCCCTCGTT (the underline indicates the recognition site of restriction endonuclease NotI).

[0057] The synthetic lipase RCL gene SEQ ID NO: 1 was used as a template and PCR amplification was performed using the above primers. The PCR amplification system was: 1 μL template, 1 μL upstream primer RCL-F, 1 μL downstream primer RCL-R, 10 μL 5×PS Buffer, 4 μL dNTPs (2.5 mM), 1 μL Primer-Star DNA polymerase, and 32 μL ddH2O. The total reaction system was 50 μL. The PCR cycle program was: pre-denaturation at 95°C for 5 min, 30 cycles: 94°C for 30 sec, 56°C for 30 sec, 72°C for 1 min, 72°C for 10 min; the PCR product was recovered from the gel, digested with EcoRI and NotI, and then connected with the pET-28a vector that had been digested with the same enzymes at 16°C overnight and transformed into Escherichia coli DH5a, spread on LB+Kana plates, and inverted culture at 37°C. After the transformants appeared, the positive clones were verified by colony PCR, and the correct recombinant plasmid pET-RCL was finally obtained after sequencing verification.

[0058] 1.2 Amplification and screening of lipase mutant genes

[0059] In order to improve the specific activity of lipase RCL, the applicant screened a large number of mutations of the enzyme through directed evolution technology, using the RCL gene as a template, the above-mentioned primers RCL-F1 and RCL-R1, and the GeneMorph II random mutation PCR kit (Stratagene) for PCR amplification, gel recovery PCR product, EcoR I and Not I after enzyme digestion, and then connected with the pET-28a vector after the same enzyme digestion, transformed into Escherichia coli BL21 (DE3), coated on LB + Kana plates, inverted culture at 37°C, after the transformants appeared, they were picked one by one with a toothpick to a 96-well plate, 150ul of LB + Kana medium containing 0.1mM IPTG was added to each well, and the cells were cultured at 37°C and 220rpm for about 6h, centrifuged and the supernatant was discarded, the bacteria were resuspended in buffer, and the cells were repeatedly frozen and thawed to obtain Escherichia coli cell lysate containing lipase.

[0060] The enzyme activity of lipase was determined at 37°C and pH 8.0. 20 μL of lysate was taken out to a new 96-well plate, and 80 μL of substrate solution was added (the substrate solution was prepared by slowly mixing solution A and solution B in a ratio of 1:9 and preparing it immediately before use. Solution A: 18 mg of p-nitrophenol palmitate was accurately weighed and dissolved in 30 ml of isopropanol. Solution B: 50 mmol / L phosphate buffer pH 8.0), reacted at 37°C for 10 min, and then 80 μL of anhydrous ethanol was added to terminate the reaction, and the absorbance was measured at 410 nm.

[0061] The experimental results showed that some mutations had no effect on the specific activity of lipase RCL, and some mutations even made it worse, which did not meet the requirements. Finally, the applicant screened out mutation sites that could significantly improve the specific activity of lipase RCL without affecting its original enzymatic properties: E287S, V306T, E335A, and D359L.

[0062] Based on the wild-type lipase RCL, the present invention provides mutants comprising single mutation sites E287S, V306T, E335A and D359L, respectively, and the amino acid sequences thereof are SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0063] The above single point mutants were amplified by PCR using primers RCL-F2 and RCL-R2, and Xba I sites were introduced at both ends of the primers. The PCR reaction conditions were: denaturation at 94°C for 5 min, then denaturation at 94°C for 30 s, annealing at 56°C for 30 s, extension at 72°C for 1 min, and after 30 cycles, incubation at 72°C for 10 min.

[0064] The primer sequences are as follows:

[0065] RCL-F2: GCA GGTACC ATGCGCGGCCTCTACTCCCTGGG (underlined is the restriction endonuclease KpnI recognition site);

[0066] RCL-R2:GGC TCTAGA TTACTCGTCGACGGCGAAGCG (the underline indicates the restriction endonuclease XbaI recognition site).

[0067] The gene fragment of wild-type lipase RCL was amplified by the same PCR method as above.

[0068] 1.3 Construction of Pichia pastoris engineered strains

[0069] The wild-type lipase RCL and its mutant genes cloned above were respectively connected to the expression vector pPIC9K through EcoRI and NotI sites to construct an expression vector.

[0070] The expression vector was linearized with Sal I, and the linearized fragment of the expression vector was transformed into Pichia pastoris GS115 by electroporation. The recombinant strains of Pichia pastoris were screened on MD plates, and then multi-copy transformants were screened on YPD plates containing different concentrations of geneticin.

[0071] The screened transformants expressing the recombinant lipase single-point mutant were transferred to BMGY medium, cultured at 30°C and 220rpm for 1 day; then transferred to BMMY medium, cultured at 30°C and 220rpm; 0.5% methanol was added every day to induce expression for 4 days; the bacteria were removed by centrifugation, and the fermentation supernatant was analyzed by SDS-PAGE electrophoresis. The results showed that the molecular weight of the recombinantly expressed lipase mutant in the fermentation supernatant was about 40kDa, which was the same as the theoretical molecular weight.

[0072] 1.4 Lipase activity detection

[0073] (1) Definition of lipase activity unit

[0074] Under the conditions of 40°C and pH 7.5, the amount of enzyme required to hydrolyze the substrate to produce 1 μmol of titratable fatty acid in 1 min is one enzyme activity unit U.

[0075] (2) Enzyme activity determination method

[0076] Weigh 40g of polyvinyl alcohol (PVA: degree of polymerization 1750±50), add 800ml of water, soak for 4-6h, heat in a boiling water bath, stir until completely dissolved, stir and cool, then make up to 1000ml, filter with 6-8 layers of clean gauze, and set aside the filtrate.

[0077] Take 150 ml of the above filtrate, add 50 ml of olive oil, and process with a high-speed homogenizer for 10 minutes (processed 4 times, with an interval of 5 minutes, and each processing for 2-3 minutes), and a milky white PVA emulsion is obtained. Prepare it before use.

[0078] Take two 100ml Erlenmeyer flasks, add 4ml of substrate solution and 5ml of pH 7.5 phosphate buffer to the blank bottle (A) and the sample bottle (B), respectively, then add 15ml of 95% ethanol to the blank bottle (A), and preheat in a 40℃ water bath for 5min;

[0079] Add 1 ml of the enzyme solution to be tested to the blank bottle (A) and the sample bottle (B), mix well and time immediately. After the reaction lasts for 15 minutes, use a sample pipette to immediately add 15 ml of 95% ethanol to the sample bottle (B) to terminate the reaction and take it out;

[0080] Pour the above reaction solution into a 50ml beaker, add 5ml of pure water to the conical flask, shake well and pour into the 50ml beaker, add 2 drops of phenolphthalein indicator;

[0081] Using a pH meter calibrated for alkaline conditions, add 0.05 mol / L sodium hydroxide solution to the beaker under stirring and titrate to a pH of 9.92. Titrate until the pH value does not change within 20 seconds as the endpoint, and record the volume of the sodium hydroxide standard solution consumed.

[0082] Enzyme activity calculation formula:

[0083] X——lipase activity, U / ml;

[0084] V1——the volume of sodium hydroxide standard solution consumed when titrating the sample, ml;

[0085] V2——the volume of sodium hydroxide standard solution consumed when titrating the blank, ml;

[0086] C——Concentration of sodium hydroxide standard solution, mol / L;

[0087] 50——1ml of 0.05mol / L sodium hydroxide solution is equivalent to 50μmol of fatty acid;

[0088] n——enzyme solution dilution multiple;

[0089] 0.05——Conversion coefficient of sodium hydroxide standard solution concentration;

[0090] 15——Time conversion factor.

[0091] (3) Enzyme activity assay results

[0092] The enzyme activity of the fermentation supernatant was determined according to the above method. The results showed that the enzyme activity of the fermentation supernatant of Pichia pastoris expressing wild-type lipase was 405 U / ml, while the enzyme activity of the fermentation supernatant of Pichia pastoris expressing mutant lipase reached 421-580 U / mL.

[0093] 1.5 Fermentation verification

[0094] The Pichia pastoris expressing the wild-type lipase RCL and its mutants were fermented in 10-liter fermenters respectively. The culture medium formula used for the fermentation was: 1.1 g / L calcium sulfate, 5.5 g / L potassium dihydrogen phosphate, 55 g / L ammonium dihydrogen phosphate, 20.3 g / L potassium sulfate, 16.4 g / L magnesium sulfate, 1.65 g / L potassium hydroxide, and 0.05% defoamer.

[0095] Fermentation process: pH 5.0, temperature 30°C, stirring rate 300rpm, ventilation volume 1.0-1.5 (v / v), dissolved oxygen controlled above 20%.

[0096] The whole fermentation process is divided into three stages: the first stage is the bacterial culture stage, inoculated with seeds at a ratio of 7%, cultured at 30°C for 24-26 hours, and marked by the completion of glucose supplementation; the second stage is the starvation stage, when glucose is supplemented, no carbon source is added, and when the dissolved oxygen rises to more than 80%, it indicates that this stage ends, which lasts for about 30-60 minutes; the third stage is the induction expression stage, in which methanol is added for induction, and the dissolved oxygen is kept above 20%, and the culture time is between 150-180 hours. After the fermentation is completed, the fermentation liquid is processed by a plate and frame filter to obtain a crude enzyme liquid.

[0097] The crude enzyme solution was tested for enzyme activity using the lipase activity assay method described in 1.4 of Example 1. The results showed that the final fermentation enzyme activity of Pichia pastoris expressing the wild-type lipase was 15373 U / ml, while the final fermentation enzyme activity of Pichia pastoris expressing the single-point mutant of lipase reached 18534-23939 U / ml.

[0098] 1.6 Determination of lipase enzymatic properties

[0099] (1) Optimal pH

[0100] The lipase activity of the crude fermentation enzyme solution described in 1.4 of Example 1 was determined at 30° C. using disodium hydrogen phosphate-citrate buffer with pH values ​​of 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0, respectively, and the relative enzyme activity was calculated with the highest enzyme activity as 100%.

[0101] The results showed that the optimal pH value for wild-type lipase RCL and the mutant was 8.0, and the relative enzyme activity levels under different pH conditions were not much different.

[0102] (2) Optimum working temperature

[0103] The lipase activity of the crude enzyme solution described in 1.3 of Example 1 was determined at 20°C, 25°C, 30°C, 35°C, 40°C, 50°C, 60°C, 70°C, and 80°C, pH 8.0, and the relative enzyme activity was calculated with the highest enzyme activity as 100%.

[0104] The results showed that the optimal temperature for the wild-type lipase RCL and the mutant was 35℃, and the relative enzyme activity levels under different temperature conditions were not much different.

[0105] (3) Lipase specific activity

[0106] The protein content of the fermentation supernatant of the Pichia pastoris strain expressing the above-mentioned recombinant wild-type lipase RCL and its single-point mutant was determined by the Coomassie Brilliant Blue method, and the specific activity of the enzyme was obtained by dividing the enzyme activity by the protein content. The results are shown in Table 1.

[0107] Table 1 Analysis of specific activity of lipase mutants

[0108]

[0109]

[0110] From the data in Table 1, it can be seen that compared with the wild-type lipase RCL, the mutants provided by the present invention comprising single mutation sites E287S, V306T, E335A and D359L respectively have a specific activity increased by 17.1%-64.9%, and the effect is significant.

[0111] Example 2 Lipase mutation combination screening

[0112] In order to further improve the specific activity of lipase, the four mutation sites screened in Example 1 were combined and screened, and the recombinantly expressed combined mutants were respectively tested for specific activity. The results showed that the E287S / V306T two-point mutation combination, the E287S / V306T / E335A three-point mutation combination, and the E287S / V306T / E335A / D359L four-point mutation combination can significantly improve the specific activity of lipase. The specific results are shown in Table 2.

[0113] Table 2 Analysis of specific activity of lipase mutants

[0114] Lipase Specific activity (u / mg) Wild-type RCL 4590 E287S / V306T double point mutant 7790 E287S / V306T / E335A triple point mutant 10191 E287S / V306T / E335A / D359L quadruple mutant 10229

[0115] From the data in Table 2, it can be seen that compared with the wild-type lipase RCL, the mutants provided by the present invention comprising two-point mutation E287S / V306T, three-point mutation E287S / V306T / E335A and four-point mutation E287S / V306T / E335A / D359L respectively have increased specific activity by 69.7%-122.9%, which is a very significant effect.

[0116] The lipase mutants comprising two-point mutation E287S / V306T, three-point mutation E287S / V306T / E335A and four-point mutation E287S / V306T / E335A / D359L have amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0117] The above results show that the single mutation sites E287S, V306T, E335A, D359L and their combination provided by the present invention can significantly improve the specific activity of wild-type lipase RCL, thereby significantly reducing the production cost of lipase, which is conducive to promoting the wide application of the enzyme.

[0118] Example 3 Preparation of immobilized lipase and its application in OPL synthesis

[0119] 3.1 Preparation of immobilized lipase

[0120] 500 ml of the concentrated enzyme solution of the above lipase mutant was taken, and 100 g of macroporous resin was added, and stirred at 30° C. and 200 rpm for 12 h. After stirring, the solution was filtered, and the resin was dried in a fluidized bed to obtain immobilized lipase.

[0121] 3.2 Preparation of OPL structured lipids

[0122] Take 100g of palmitic acid stearin, add 300g of oleic acid, 400g of linoleic acid, and 15g of immobilized lipase, and stir at 60°C and 300rpm for 12h. After stirring, the solution is filtered, and after the immobilized lipase is separated, the contents of OPO, OPL, and LPL in the reaction solution are detected by high performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD).

[0123] The results showed that the immobilized lipase mutant provided by the present invention catalyzed the transesterification of palmitic stearin with oleic acid and linoleic acid, and the content of OPL in the generated reaction solution was as high as 2.74-4.14%, and the contents of OPO and LPL were 0.96-1.50% and 1.85-2.65% respectively.

[0124] The lipase mutant provided by the invention can be widely used in synthesizing functional lipid OPL, and has broad application prospects.

[0125] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A lipase mutant, characterized in that: The mutant comprises an amino acid sequence having at least 90% identity with SEQ ID NO:2, and comprises an amino acid substitution at at least one position selected from the following group: 287, 306, 335, 359 compared to SEQ ID NO:

2.

2. The mutant according to claim 1, characterized in that The amino acid sequence of the mutant is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to SEQ ID NO:

2.

3. The mutant according to claim 2, characterized in that The mutant comprises substitution of at least one amino acid selected from the group consisting of E287S, V306T, E335A, and D359L.

4. The mutant according to claim 3, characterized in that The mutant comprises a substitution or combination of at least one amino acid in the following group: E287S; V306T; E335A; D359L; E287S / V306T; E287S / E335A; E287S / D359L; V306T / E335A; V306T / D359L; E335A / D359L; E287S / V306T / E335A; E287S / V306T / D359L; E287S / E335A / D359L; V306T / E335A / D359L; E287S / V306T / E335A / D359L.

5. The mutant according to claim 4, characterized in that The amino acid sequence of the mutant is SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO:

9.

6. A DNA molecule encoding the lipase mutant according to any one of claims 1 to 5.

7. A recombinant expression vector comprising the DNA molecule of claim 6.

8. A host cell comprising the recombinant expression vector according to claim 7.

9. The host cell according to claim 8, characterized in that The host cell is Pichia pastoris ( Pichia pastoris ) or Aspergillus niger ( Aspergillus niger ) or Trichoderma reesei ( Trichoderma reesei ).

10. Use of the lipase mutant according to any one of claims 1 to 5 in the synthesis of functional lipid OPL.

Citation Information

Patent Citations

  • Lipase mutant with improved thermal stability and application thereof

    CN111944783A

  • Lipase mutant and application thereof in white spirit yellow water treatment

    CN115786302A

  • Rhizopus oryzae lipase mutant and application thereof

    CN118308327A

  • Engineering of rhizopus oryzae lipase to increase its thermostability for the production of structured triacylglycerols

    WO2023158372A2

Cited By

  • High-temperature-resistant lipase mutant and application thereof in synthesis of functional lipid

    CN119372178A